What is Trelegy Ellipta?
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA).
Trelegy Ellipta contains three active substances; an inhaled corticosteroid (fluticasone furoate) and two bronchodilators (umeclidinium and vilanterol). 1
For safety information on Trelegy Ellipta including information on who is suitable for a Trelegy prescription, please see the Trelegy Ellipta patient information leaflet link below.